We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights NVIDIA, Palantir, Coca-Cola, Kewaunee Scientific and Natural Health Trends
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 8, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Palantir Technologies Inc. (PLTR - Free Report) , The Coca-Cola Co. (KO - Free Report) , Kewaunee Scientific Corp. (KEQU - Free Report) and Natural Health Trends Corp. (NHTC - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for NVIDIA, Palantir and Coca-Cola
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Palantir Technologies Inc. and The Coca-Cola Co., as well as two micro-cap stocks Kewaunee Scientific Corp. and Natural Health Trends Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
NVIDIA’s shares have outperformed the Zacks Semiconductor - General industry over the year-to-date period (+33.6% vs. +30.9%). The company is benefiting from the strong growth of artificial intelligence (AI) and high-performance, accelerated computing. The growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA’s Hopper and Blackwell architectures is aiding data center revenues.
The continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. Collaborations with more than 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicle space.
The Zacks analyst expects NVIDIA’s revenues to witness a CAGR of 29% through fiscal 2026-2028. However, a limited supply of Blackwell GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins.
Shares of Palantir have outperformed the Zacks Internet - Software industry over the past year (+513.2% vs. +52.9%). The company’s AI strategy, driven by Foundry, Gotham and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. Notable defense projects, like Open DAGIR, and AIP boot camps for commercial clients boost customer acquisition.
With $5.4 billion in cash, no debt and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues and increased investor visibility. Meanwhile, PLTR's reluctance to dividend payout is a green flag for dividend-seeking investors. Intense competition from tech giants and rising costs amidst a rapidly evolving AI landscape and an elevated valuation challenge its appeal.
Coca-Cola’s shares have outperformed the Zacks Beverages - Soft drinks industry over the year-to-date period (+13.4% vs. +5.5%). The company delivered a strong second-quarter 2025, with top- and bottom-line improving year over year, driven by continued business momentum, aided by enhanced pricing across markets.
The second-quarter 2025 performance was driven by broad-based growth, improved price/mix, and effective execution of its all-weather strategy, which blends marketing, innovation, and revenue growth management. Innovation and marketing continue to drive brand momentum, with impactful campaigns and product launches.
However, Coca-Cola has faced notable volume pressure in key markets in second-quarter 2025, reflecting evolving consumer behavior and economic challenges, particularly in North America and Europe. Currency headwinds, higher taxes, and rising interest costs continue to be concerns.
Shares of Kewaunee Scientific Corp. have outperformed the Zacks Instruments - Scientific industry over the past year (+20.8% vs. -50.7%). This microcap company with a market capitalization of $157.22 million has strengthened its market position through the Nu Aire acquisition, boosting domestic sales 30.7% and expanding its life sciences portfolio. This strategic move enhanced product breadth and added high-margin distribution channels, driving the gross margin to 28.6%.
A record $214.6-million backlog offers strong revenue visibility for fiscal 2026. Domestic segment momentum is robust, contributing ~75% to total sales with rising EBITDA and operating leverage. Adjusted EBITDA rose nearly 30% despite $6 million in one-time costs, showcasing disciplined execution.
However, international profitability remains weak due to execution inefficiencies and India-centric risks. Post-acquisition cost structure and leverage are elevated, pressuring margins. High customer concentration and exposure to input cost volatility also constrain upside.
Shares of Natural Health Trends have outperformed the Zacks Consumer Products - Discretionary industry over the year-to-date period (+17.4% vs. -9.1%). This microcap company with a market capitalization of $55.95 million remains anchored in Hong Kong, contributing 83.3% of 2025 year-to-date sales, with resilient demand despite tariff-related headwinds.
Its launch into the South American country of Colombia marks strategic diversification, enhancing its Latin American footprint. Robust gross margin (73.8%) and disciplined SG&A spending support cost efficiency, while steady cash reserves ($34.2 million) and no debt ensure financial flexibility. Membership stabilized at 29,260, aided by training and incentives.
Yet, revenue remains volatile due to macro pressures and Hong Kong concentration. Membership attrition, weak international traction and rising commission expenses limit scalability. Supply chain realignment offers long-term agility but poses short-term execution risks. The valuation reflects investor caution, but also highlights potential upside given NHTC’s global expansion efforts.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights NVIDIA, Palantir, Coca-Cola, Kewaunee Scientific and Natural Health Trends
For Immediate Release
Chicago, IL – August 8, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Palantir Technologies Inc. (PLTR - Free Report) , The Coca-Cola Co. (KO - Free Report) , Kewaunee Scientific Corp. (KEQU - Free Report) and Natural Health Trends Corp. (NHTC - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for NVIDIA, Palantir and Coca-Cola
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Palantir Technologies Inc. and The Coca-Cola Co., as well as two micro-cap stocks Kewaunee Scientific Corp. and Natural Health Trends Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
Today's Featured Research Reports
NVIDIA’s shares have outperformed the Zacks Semiconductor - General industry over the year-to-date period (+33.6% vs. +30.9%). The company is benefiting from the strong growth of artificial intelligence (AI) and high-performance, accelerated computing. The growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA’s Hopper and Blackwell architectures is aiding data center revenues.
The continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. Collaborations with more than 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicle space.
The Zacks analyst expects NVIDIA’s revenues to witness a CAGR of 29% through fiscal 2026-2028. However, a limited supply of Blackwell GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins.
(You can read the full research report on NVIDIA here >>>)
Shares of Palantir have outperformed the Zacks Internet - Software industry over the past year (+513.2% vs. +52.9%). The company’s AI strategy, driven by Foundry, Gotham and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. Notable defense projects, like Open DAGIR, and AIP boot camps for commercial clients boost customer acquisition.
With $5.4 billion in cash, no debt and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues and increased investor visibility. Meanwhile, PLTR's reluctance to dividend payout is a green flag for dividend-seeking investors. Intense competition from tech giants and rising costs amidst a rapidly evolving AI landscape and an elevated valuation challenge its appeal.
(You can read the full research report on Palantir here >>>)
Coca-Cola’s shares have outperformed the Zacks Beverages - Soft drinks industry over the year-to-date period (+13.4% vs. +5.5%). The company delivered a strong second-quarter 2025, with top- and bottom-line improving year over year, driven by continued business momentum, aided by enhanced pricing across markets.
The second-quarter 2025 performance was driven by broad-based growth, improved price/mix, and effective execution of its all-weather strategy, which blends marketing, innovation, and revenue growth management. Innovation and marketing continue to drive brand momentum, with impactful campaigns and product launches.
However, Coca-Cola has faced notable volume pressure in key markets in second-quarter 2025, reflecting evolving consumer behavior and economic challenges, particularly in North America and Europe. Currency headwinds, higher taxes, and rising interest costs continue to be concerns.
(You can read the full research report on Coca-Cola here >>>)
Shares of Kewaunee Scientific Corp. have outperformed the Zacks Instruments - Scientific industry over the past year (+20.8% vs. -50.7%). This microcap company with a market capitalization of $157.22 million has strengthened its market position through the Nu Aire acquisition, boosting domestic sales 30.7% and expanding its life sciences portfolio. This strategic move enhanced product breadth and added high-margin distribution channels, driving the gross margin to 28.6%.
A record $214.6-million backlog offers strong revenue visibility for fiscal 2026. Domestic segment momentum is robust, contributing ~75% to total sales with rising EBITDA and operating leverage. Adjusted EBITDA rose nearly 30% despite $6 million in one-time costs, showcasing disciplined execution.
However, international profitability remains weak due to execution inefficiencies and India-centric risks. Post-acquisition cost structure and leverage are elevated, pressuring margins. High customer concentration and exposure to input cost volatility also constrain upside.
(You can read the full research report on Kewaunee Scientific Corporation here >>>)
Shares of Natural Health Trends have outperformed the Zacks Consumer Products - Discretionary industry over the year-to-date period (+17.4% vs. -9.1%). This microcap company with a market capitalization of $55.95 million remains anchored in Hong Kong, contributing 83.3% of 2025 year-to-date sales, with resilient demand despite tariff-related headwinds.
Its launch into the South American country of Colombia marks strategic diversification, enhancing its Latin American footprint. Robust gross margin (73.8%) and disciplined SG&A spending support cost efficiency, while steady cash reserves ($34.2 million) and no debt ensure financial flexibility. Membership stabilized at 29,260, aided by training and incentives.
Yet, revenue remains volatile due to macro pressures and Hong Kong concentration. Membership attrition, weak international traction and rising commission expenses limit scalability. Supply chain realignment offers long-term agility but poses short-term execution risks. The valuation reflects investor caution, but also highlights potential upside given NHTC’s global expansion efforts.
(You can read the full research report on Natural Health Trends here >>>)
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.